Zeiss Ventures Research
Investment Thesis
ZEISS Ventures is the corporate venture capital arm of the ZEISS Group, the German optics and optoelectronics conglomerate headquartered in Oberkochen. Its stated mission is "to enable and accelerate the development and commercialization of market-shaping innovations which are between, beyond, or disruptive to the current ZEISS Strategic Business Units." As a strategic corporate investor, it backs deep-tech start-ups that go beyond ZEISS's existing core businesses (Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology, and Consumer Markets) but remain strategically adjacent to them. The unit is organized into three functions: External Venturing (identifying and investing in outside start-ups, actively managing the investment portfolio and door-opening within ZEISS), Internal Venturing (supporting and financing early-stage business development projects originating inside ZEISS), and Beyond Innovation (high-risk exploration of markets and technologies beyond ZEISS's current fields).
Sector Focus
ZEISS Ventures organizes its external search into four clusters: MedTech & Life Sciences (AI & image analysis, diagnostics & monitoring, microscopy, microsurgery, ophthalmology), Photonics & Optics/Semiconductor (advanced packaging, enabling technologies, next-gen eyewear, optical sensors, photonic integrated circuits), Industrial Technology (advanced sensors, industrial metrology, machine vision & AI, robotics & automation), and Explorative Verticals (AI, CRT technology roadmap, disruptive optical technology, tissue engineering). In practice the bulk of recent deal flow has landed in ophthalmology/medtech (Custom Surgical, Maculaser, Odne, Hypervision Surgical, LinkoCare) and photonics/semiconductor deep tech (Lidrotec, SeeTrue Technologies, ZOMP).
Stage Focus
ZEISS Ventures targets start-ups at the pre-Series A to Series A stage, and its portfolio confirms this — most disclosed rounds are labeled Pre-Series A or Series A/Series A-2. It occasionally participates in later or bridge rounds for existing portfolio companies (e.g., Maculaser's structured first-close round).
Check Size
The firm states a typical initial ticket size of €500K–€5M. Recent disclosed round sizes it has joined range from roughly $2.5M (SeeTrue) up to $13.5M (Lidrotec Series A-2), reflecting that ZEISS Ventures is usually one participant in a syndicated round rather than writing the entire check itself.
Lead Tendency
ZEISS Ventures has both led (SeeTrue Technologies, €2.2M round) and co-led (Maculaser, alongside M2care) recent rounds, but more commonly appears as a strategic participant alongside financial VCs (Lidrotec alongside Lam Capital and Goose Capital; arcoris bio's oversubscribed CHF 6.3M round; Odne; Custom Surgical). Treat lead tendency as mixed/unclear from a purely financial-lead perspective, though it clearly takes an active, hands-on ownership role once invested.
Recent Activity
ZEISS Ventures has been actively deploying through 2025 and 2026:
- June 2025: Participated in Lidrotec's $13.5M Series A-2 for laser-based chip singulation.
- June 2025: Invested in Odne, a Swiss dental technology start-up, to fund US market entry.
- November 2025: Participated in arcoris bio's oversubscribed CHF 6.3M round for biomedical diagnostics.
- February 2026: Participated in Custom Surgical's EUR 3.5M Pre-Series A for ophthalmology workflow digitization.
- May 2026: Co-led (with M2care) Maculaser's funding round for temperature-controlled retinal laser therapy.
- August 2026: Led a EUR 2.2M round in SeeTrue Technologies for miniaturized eye-tracking hardware.
The firm hosted ZEISS Ventures Day 2025 on September 23, 2025, drawing more than 250 innovators, entrepreneurs, and external investors — signaling an active, visible presence in the deep-tech venture ecosystem. One portfolio company, Scantinel Photonics (LiDAR-on-a-chip), went through insolvency proceedings in late 2025, with its business and assets acquired by MicroVision; ZEISS Ventures lists this internally as a 2025 exit.
Portfolio Highlights
Current active portfolio spans ophthalmology/medtech (Mindpeak — AI digital pathology; Hypervision Surgical — intraoperative hyperspectral imaging; InSphero — 3D cell culture models used by major pharma; Surgify Medical — surgical power tools; Odne — endodontics; LinkoCare — sight-restoration devices; SeeTrue Technologies — eye tracking; Maculaser — retinal laser therapy; Custom Surgical — ophthalmology workflow digitization; arcoris bio — biomedical diagnostics) and deep tech/photonics (ZOMP — 3D imaging flow cytometry, a University of Cambridge spinout; Morrow — liquid-crystal multifocal eyewear; Vibrosonic — MEMS-based non-surgical hearing aid; Lidrotec — laser chip-cutting for semiconductors; ZEISS MicroOptics — invisible microstructured optics). Past exits/spin-ins include Nanoscribe (3D microprinting, exited 2021), Bridger Photonics (precision LiDAR, exited 2022), tooz technologies (data glasses, spun into ZEISS in 2024), and ZEISS MultiSEM (parallel-beam electron microscopy, exited 2018).
Team
ZEISS Ventures is a 22-person, internationally distributed team spanning External Venturing, Internal Venturing, Beyond Innovation, Operations, and Controlling functions:
- Dr. Boris Hofmann — Head of ZEISS Ventures
- Dr. Marc Schüler — Head of External Venturing
- Evgeni Rehfuss — Head of Internal Venturing
- Mike Gänßler, Johannes Hofmann, Benedikt Kläs, Julian Schroth, Annie Tao, Niklas Urchs — External Venturing
- Azhad Azhar, Timo Fürbaß, Marina Lecas, Nina Mathers Voigt, Dr. Daisy Paiva, Dr. Philipp Topic — Internal Venturing
- Simon Anetsmann, Murat Kaplan, Dr. Marcel Röder — Beyond Innovation
- Christina Giantsiou, Johanna Hahn, Sophia Lang — Operations
- Lisa Ullrich — Controlling
Two ZEISS Executive Board members sit on the Venture Board, which makes final investment decisions alongside the Ventures management team.
Decision Process
Structured and board-governed: dedicated venture owners manage each portfolio company day to day, but the Venture Board — including two Executive Board members — makes the ultimate investment calls. This points to an investment-committee-style process rather than a solo-GP or flat-partnership model.
Founder Preferences
ZEISS Ventures favors deep-tech, hardware-and-software founding teams building B2B-scalable products with a demonstrated path to product-market fit, particularly where the technology could open new capabilities for or disrupt an existing ZEISS Strategic Business Unit. It explicitly states it will not compromise ZEISS's brand or long-term thinking for short-term financial motivations alone, suggesting a preference for founders comfortable with a strategic, patient partner over a purely financial one.
Geographic Focus
Primarily Europe (Germany, Switzerland, Finland, Sweden) and North America, consistent with its stated focus: "Our business portfolio is international and we focus on Europe and North America."
Key Facts
Six years as an active venture partner, 22 team members, 15+ global investments, a fund size exceeding $150M, and three realized exits to date (plus additional spin-ins/spin-outs and one insolvency-driven asset sale in 2025).